Print this Page for Your Records Close Window

Control/Tracking Number: 07-A-209-ISCT
Activity: Abstract
Current Date/Time: 4/5/2008 9:09:16 AM

HEART FAILURE (HF) IMPROVEMENT BY MINIMALLY INVASIVE DELIVERY OF AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS (ABMMC) TRANSPLANTATION. LONG TERM FOLLOW-UP


Author Block: J. Tuma-Mubarack1, R. Fernandez-Viña2, A. A. Carrasco-Yalan3, J. Castillo-Aguirre3, C. Cruz1, A. Carrillo1, J. Ercilla1, G. Valenzuela1, C. Yarleque1, J. Cunza1, S. Chirinos1, A. N. Patel1;
1Division of Interventional Cardiology and Regenerative Medicine, Clínica San Felipe, Clínica Ricardo Palma, Clínica Maison de Santé, Lima, PERU, 2Centro Cardiovascular San Nicolás, Don Roberto Fernandez-Viña Foundation, San Nicolas, ARGENTINA, 3Instituto de Criopreservación y Terapia Celular, Lima, PERU.

Abstract:
Background: Studies suggest that intracoronary transplantation of unselected ABMMC cells may improve LVEF in HF
Methods: 18 patients with ejection fraction < 35% were recruited. Six patients were in the control and 12 in the ABMMC group, median age 65 y.o., F/M 1/8. All of cohort had NYHA class of III with maximal medical therapy. In the ABMMC group, the median number of MN and CD34+ cells infused were 8.1*108 and 1.2*107 respectively delivered retrograde via coronary sinus.
Results: Patients in the BMC group had relief of dyspnea symptoms and improvement in functional class. At 1 year, NYHA class improved in 92% of the patients in the BMC group by at least 1 class. At 1 year follow-up there the differences between the ABMMC and the control group either at stress SPECT LVEF (6.72% vs 0.11%, p<0,001) or rest SPECT LVEF (6.18% vs 1.14%, p=0.029). Changes assessment of end-diastolic and end-systolic volumes (ESV) between groups shows trend only in the ESV by stress SPECT (Δ ESV control = -0.17 cc vs Δ ESV BMC = 15.17 cc, p=0.06). The ABMMC group was followed for 2 years (t 1): the stress LEVF at baseline, 1 and 2 years were 30.8%, 35.9% and 33% respectively (p=0.006); the rest LEVF at baseline, 1 and 2 years were 30.7%, 34.0% and 35.2% respectively (p=0.004).
Conclusions: Infusion of ABMMC into the coronary sinus is safe and feasible in the ischemic HF. It is associated with significant improvement in symptoms and potential outcome durability of LVEF.

:


Topic (Complete):  Hematopoietic stem cells—clinical
Presentation Preference (Complete):  Please do NOT consider my abstract for oral presentation
Keyword (Complete):  bone marrow ; heart failure ; cellular therapy
Travel Awards (Complete):
     Young Investigator Awards (for residents, fellows and students) : True
     

Status: Complete
International Society for Cellular Therapy Head Office
375 West 5th Avenue, Suite 201
Vancouver, BC V5Y 1J6 Canada
Phone: (604) 874-4366
Fax: (604) 874-4378
isct@celltherapysociety.org

 

 

LETTER OF INVITATION

 

From: katherine.clark@malachite-mgmt.com

To: antonio1carrasco@hotmail.com

Date: Thu, 20 Mar 2008 13:52:12 -0700

Subject: ISCT 2008 Notification of Abstract Acceptance

Dear Jorge Tuma-Mubarack,

 

Re: Your abstract titled “ HEART FAILURE (HF) IMPROVEMENT BY MINIMALLY INVASIVE DELIVERY OF AUTOLOGOUS BONE MARROW MONONUCLEAR CELLS (ABMMC) TRANSPLANTATION. LONG TERM FOLLOW-UP

 

We are pleased to inform you that your abstract has been accepted for a poster presentation at the ISCT 2008 Annual Meeting in Miami.  Your permanent abstract number is: 142

 

Poster board dimensions will measure 4 feet high X 8 feet wide ( 1.2 metres high by 2.4 metres wide).  Posters should not exceed these dimensions. 

 

Posters will be set up in the River Front Hall of the Hyatt Regency Miami.

 

Please note that there will be two poster viewing sessions; your poster is in Poster Session 2, which will take place on Monday, May 19 from 5:00 to 6:00 pm .  As Poster Session 1 will take place on Sunday, May 18, poster set-up for your session will take place on Monday, May 19 from 7:00 to 9:00 am. We ask that you remove your poster on Tuesday, May 20 between 2:00 and 4:00 pm. ISCT will remove any posters left up after this time, and is not responsible for any lost posters; any unclaimed posters will be disposed of.

 

Abstract authors should be present by the poster during their poster viewing session.  Poster viewing will also occur throughout the conference, but authors are only required to attend their poster during the Poster Viewing session.

 

Abstract authors are required to register for the ISCT 2008 conference.  ISCT encourages those planning to attend ISCT 2008 to register before the Regular Registration deadline of April 30, 2008.  Delegates can register online at

http://www.celltherapysociety.org/Meetings/Annual_Meeting/Registration.aspx .  

 

Please let us know if you have any questions or concerns about your abstract presentation or the ISCT 2008 Annual Meeting.  We look forward to seeing you in Miami!

 

Sincerely,

 

Katherine Clark

ISCT Meeting Coordinator

375 West 5th Avenue, Suite 201

Vancouver, BC V5Y 1J6  Canada

T :     604-874-4366

F :     604-874-4378

E :      katherine.clark@malachite-mgmt.com

Website : www.celltherapysociety.org